Indeed, synergistic effects have been shown for co-targeting both ROR1 and the BCR or BCL-2 family, underlining the large potential for ROR1-targeted therapies in overcoming MCL and CLL drug resistance [106,108]. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.